Question 1

What is Cartalax and how is it classified?

Accepted Answer

Cartalax (also transliterated Kartalax) is a synthetic short-peptide bioregulator - the tripeptide Ala-Glu-Asp (AED, lab code T-31) - developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is a Research Use Only material, not an approved medicine. Note that it is a distinct molecule from Epitalon (AEDG, a tetrapeptide); some non-scientific vendor pages incorrectly list Cartalax as AEDG, but the peer-reviewed literature consistently defines it as the AED tripeptide.

Question 2

What does the peer-reviewed literature actually show?

Accepted Answer

According to PubMed, the indexed evidence is limited and almost entirely in vitro or in silico. Studies report increased chondrogenic markers (SOX9, aggrecan, type II collagen, COMP), reduced senescence/SASP markers in aging chondrocytes, modulation of aging-associated genes in stem cells, and proliferation and anti-apoptotic signals in cultured fibroblasts and renal cells. These are mechanistic, cell-level observations in research, not demonstrated clinical outcomes.

Question 3

Why is it grouped under longevity and joint research?

Accepted Answer

Most AED studies use cellular-aging models - replicatively aged stem cells, chondrocytes, fibroblasts, and renal cells - and the 2023 cartilage work frames it as a candidate for studying age-related cartilage and chondrocyte biology and osteoarthritis models. The longevity/joint association comes from these laboratory aging contexts, not from established effects in people.

Question 4

Is there human clinical evidence for Cartalax?

Accepted Answer

No controlled human trials specific to Cartalax/AED are indexed in PubMed, and ClinicalTrials.gov returns no registered trials. A 2023 Russian-language review (PMID 37782637) asserts oral use in older osteoarthritis patients and use in animal osteoarthritis models, but the underlying primary data are not accessible in indexed English-language literature, so human efficacy and safety remain unestablished. Pain-reduction percentages circulating on commercial sites are not traceable to verifiable peer-reviewed sources.

Question 5

What is the proposed mechanism of action?

Accepted Answer

The proposed mechanism is epigenetic/gene-regulatory: short peptides are hypothesized to interact with DNA and chromatin to influence transcription. For AED specifically, in silico molecular docking modeled binding within the DNA minor groove (PMID 25946838), and related tetrapeptide work modeled histone binding. This remains a working hypothesis supported mainly by computational modeling and cell-culture gene-expression changes rather than by definitive target validation.

Question 6

What dosing is used in this research?

Accepted Answer

This is a Research Use Only material and the following is not medical advice. Research-reported handling and concentrations vary by experimental model - for example, cell-culture studies used nanomolar concentrations or about 200 ng/mL - and no validated human dosing is established. For any protocol parameters, consult the specific protocol reference for the study in question rather than generalized figures, and treat dosing numbers found on vendor pages as unverified.

Question 7

What are the main limitations of the evidence base?

Accepted Answer

The body of work is small, largely from a single research network, concentrated in low-impact and partly non-English journals (some without DOIs), and dominated by in vitro and in silico methods with no independent replication and no controlled human data. Findings should be read as preliminary research signals warranting further study, not as established effects.

Phase	Daily reference amount	Units / volume
Weeks 1–2	2,000 mcg (2.0 mg)	30 units (0.30 mL)
Weeks 3–4	3,000 mcg (3.0 mg)	45 units (0.45 mL)
Weeks 5–8	4,000 mcg (4.0 mg)	60 units (0.60 mL)
Weeks 9–12	5,000 mcg (5.0 mg)	75 units (0.75 mL)

Cartalax.

Calculated volume reference

Cited protocol & reconstitution guide